DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ: DMAA · FINANCIAL SERVICES · SHELL COMPANIES
$10.53
-0.28% today
Updated 2026-04-30
Market cap
$355.55M
P/E ratio
55.50
P/S ratio
—
EPS (TTM)
$0.19
Dividend yield
—
52W range
$10 – $11
Volume
0.2M
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | — | $0.00 |
| Revenue growth (YoY) | — | — |
| Cost of revenue | — | — |
| Gross profit | — | — |
| Gross margin | — | — |
| R&D | — | — |
| SG&A | $479.00 | $2.82M |
| Operating income | $-479.00 | $-2.82M |
| Operating margin | — | — |
| EBITDA | — | $-2.82M |
| EBITDA margin | — | — |
| EBIT | — | — |
| Interest expense | — | — |
| Income tax | — | — |
| Effective tax rate | 0.0% | 0.0% |
| Net income | $-479.00 | $5.94M |
| Net income growth (YoY) | — | +1240317.7% |
| Profit margin | — | — |